SCHEMBL3574231

SCHEMBL3574231

CC(C)c1c(C(=O)N(C)Cc2ccc(Cl)cc2Cl)[nH]c(C(N)=O)c1S(=O)(=O)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
HPGD P15428 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
EPHX1 P07099 2/20 0.35
SLC6A2 P23975 3/20 0.35
SLC6A4 P31645 3/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
HDAC8 Q9BY41 2/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
HTT P42858 1/20 0.34
FFAR2 O15552 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CYP2D6 P10635 1/20 0.34
KCNH2 Q12809 1/20 0.34
PSEN1 P49768 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3579136 0.91 MAP2 (0.34) CRHBPCRHR2HPGDNPSR1L3MBTL1
SCHEMBL3576472 0.88 NPSR1 (0.43) CRHBPCRHR2HPGDNPSR1L3MBTL1
SCHEMBL3586340 0.87 NAMPT (0.35) LMNAFFAR2MEN1KMT2ASMN1; SMN2
SCHEMBL3587658 0.86 CRHBP (0.40) CRHBPCRHR2HPGDNPSR1L3MBTL1
SCHEMBL3585214 0.85 FFAR2 (0.34) NPSR1ALDH1A1FFAR2MEN1KMT2A
SCHEMBL3582278 0.84 LIMK2 (0.40) HPGDALDH1A1HTTMEN1KMT2A
SCHEMBL3583691 0.83 NAMPT (0.33) LMNATP53ALDH1A1HTTFFAR2
SCHEMBL3578424 0.83 LIPE (0.42) SLC6A2ALDH1A1GAAMEN1KMT2A
SCHEMBL3589851 0.82 CRHBP (0.39) CRHBPCRHR2HPGDNPSR1L3MBTL1
SCHEMBL3587755 0.81 FFAR2 (0.33) FFAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US claimed
EP-2076492-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2009-07-08 EP claimed
WO-2008054605-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2008-05-08 WO claimed
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS RTF1, RNGTT, POLR2E CRHBP 4368/4885CRHR2 4476/4885HPGD 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.